Cardiometabolic Effects of Eplerenone in HIV Infection

Exclusion Criteria

• •1. Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m\^2, serum creatinine \> 1.5 mg/dL
• •2. Serum potassium \> 5.5 mEq/L, alanine aminotransferase \> 2.5 times the upper limit of normal, hemoglobin (Hgb) \< 11 g/dL
• •3. Uncontrolled hypertension: systolic blood pressure greater than or equal to 160 mm Hg or diastolic blood pressure greater than or equal to 100 mm Hg
• •4. A blood pressure \< 90mmHg systolic or \< 50mm Hg diastolic
• •5. Screening EKG with a significant heart block (e.g. PR \> 300 ms) or an EKG determined significant by Cardiology consult.
• •6. Current hepatitis C infection, unless there has been a sustained virologic response for at least 12 months
• •7. Type 2 diabetes with microalbuminuria
• •8. Current or prior steroid use within past 6 months (except short-course or single-dose administration). Stable use of inhaled or nasal steroids are allowed.
• •9. Use of angiotensin converting enzyme (ACE) inhibitors, angiotensin reporter blockers (ARBs), potassium-sparing diuretics, and other medications that may increase the risk of hyperkalemia
• •10. Use of potassium supplementation or other medications known to increase potassium
• •11. Concomitant use of strong inhibitors and/or inducers ofof cytochrome P450 isozyme (CYP)3A4
• •12. If receiving testerone, estrogen or progesterone therapy, must be on a stable dose for at least 3 months.
• •13. Current use of growth hormone or growth hormone-releasing hormone
• •14. Current serious viral, bacterial, or other infection (excluding HIV)
• •15. Current active substance abuse/dependence
• •16. Substantial history of cardiovascular disease, including prior myocardial infarction (MI), congestive heart failure, or stroke
• •17. Contraindication to MRI
• •18. Pregnant or planning to become pregnant
• •19. Breastfeeding
• •20. Any condition that, in the opinion of the PI, may substantially increase the risk of participation